BRAF V600E (somatic)
Associated Genetic Biomarkers
AACR GENIE data is not categorized as somatic or germline. To see GENIE data for this alteration, click here.
BRAF V600E (somatic) serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E (somatic) as an inclusion criterion, 1 is phase 2 (1 open).
Trials with BRAF V600E (somatic) in the inclusion eligibility criteria most commonly target pancreatic carcinoma .
Binimetinib and encorafenib are the most frequent therapies in trials with BRAF V600E (somatic) as an inclusion criteria .
Significance of BRAF V600E (somatic) in Diseases
Pancreatic Carcinoma +
BRAF is altered in 2.49% of pancreatic carcinoma patients .
BRAF V600E (somatic) is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600E (somatic) and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.